CAPTRUST Financial Advisors
OLMA icon

CAPTRUST Financial Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6
Closed – – 4866
2021
Q3 		$0 Buy
+6
New +$162 ﹤0.01% 4724

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's OLMA Position: Q4 2021 in Review

CAPTRUST Financial Advisors sold out of Olema Pharmaceuticals (OLMA) in Q4 2021, closing a stake of 6 shares.

CAPTRUST Financial Advisors first reported a position in OLMA in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 97 funds tracked by Wall St. Rank hold OLMA as of Q4 2021.

  • CAPTRUST Financial Advisors reported no remaining Olema Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 6 Olema Pharmaceuticals shares in Q4 2021.
  • CAPTRUST Financial Advisors first reported a position in Olema Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Olema Pharmaceuticals position peaked at $0 in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.